Literature DB >> 31180921

Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program.

Russell Rosenblatt1, Shirley Cohen-Mekelburg2,3, Nicole Shen1, Zaid Tafesh1, Catherine Lucero1, Sonal Kumar1, Brett Fortune1, Sze Yan Liu4, Robert Brown1, Arun Jesudian1.   

Abstract

INTRODUCTION: Although the Hospital Readmissions Reduction Program (HRRP) has decreased readmissions in targeted conditions, outcomes in high-risk subgroups are unknown. This study analyzed the impact of cirrhosis as a comorbidity on readmissions in conditions subjected to the HRRP.
METHODS: Using a longitudinal analysis of the New York, Florida, and Washington State inpatient databases from 2009 to 2013, adult Medicare beneficiaries with a diagnosis-related group of targeted conditions by the HRRP-pneumonia, congestive heart failure (CHF), and myocardial infarction (MI)-were included. Exclusion criteria included inability to assess for readmission, previous liver transplant, or having a readmission not subject to penalty under the HRRP. A sensitivity analysis used the International Classification of Diseases, 9th Revision, Clinical Modification codes to identify pneumonia, CHF, and MI hospitalizations. The primary outcome was 30-day readmission, with secondary outcomes including 90-day readmission, trends, and cirrhosis-specific risk factors for readmission.
RESULTS: Of the 797,432 patients included, 8,964 (1.1%) had cirrhosis. Patients with cirrhosis had significantly higher 30-day readmissions overall (29.3% vs 23.8%, P < 0.001) and specifically for pneumonia and CHF, but not for MI. Thirty-day readmission rates significantly decreased in patients without cirrhosis (annual percent change -1.8%, P < 0.001), but not in patients with cirrhosis (P = 0.39). Similar findings were present for 90-day readmissions. A sensitivity analysis confirmed these findings. On multivariable analysis, cirrhosis was associated with significantly higher 30-day readmissions (odds ratio 1.13, P < 0.001). DISCUSSION: When cirrhosis is comorbid in patients with conditions subjected to the HRRP, readmissions are higher and have not improved. Focused efforts are needed to improve outcomes in cirrhosis and other high-risk comorbidities within the HRRP cohort.

Entities:  

Mesh:

Year:  2019        PMID: 31180921     DOI: 10.14309/ajg.0000000000000257

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis.

Authors:  Shirley Cohen-Mekelburg; Akbar K Waljee; Brooke C Kenney; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-09       Impact factor: 11.382

2.  An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis.

Authors:  Jeremy Louissaint; Katie Grzyb; Linda Bashaw; Rima A Mohammad; Neehar D Parikh; Elliot B Tapper
Journal:  Am J Gastroenterol       Date:  2022-03-01       Impact factor: 12.045

3.  Improved Mortality But Increased Economic Burden of Disease in Compensated and Decompensated Cirrhosis: A US National Perspective.

Authors:  Dhruvil Radadiya; Kalpit Devani; Karolina N Dziadkowiec; Chakradhar Reddy; Don C Rockey
Journal:  J Clin Gastroenterol       Date:  2021-12-31       Impact factor: 3.174

4.  Reducing readmissions in patients with cirrhosis: the time to act is now.

Authors:  Arpan Patel; Jejo D Koola; Michael E Matheny
Journal:  Ann Transl Med       Date:  2021-11

Review 5.  The Future of Quality Improvement for Cirrhosis.

Authors:  Elliot B Tapper; Neehar D Parikh
Journal:  Liver Transpl       Date:  2021-07-31       Impact factor: 6.112

6.  Identifying and mitigating factors contributing to 30-day hospital readmission in high risk patient populations.

Authors:  Michael P Rogers; Paul C Kuo
Journal:  Ann Transl Med       Date:  2021-11

7.  Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018).

Authors:  Wenyi Gu; Hannah Hortlik; Hans-Peter Erasmus; Louisa Schaaf; Yasmin Zeleke; Frank E Uschner; Philip Ferstl; Martin Schulz; Kai-Henrik Peiffer; Alexander Queck; Tilman Sauerbruch; Maximilian Joseph Brol; Gernot Rohde; Cristina Sanchez; Richard Moreau; Vicente Arroyo; Stefan Zeuzem; Christoph Welsch; Jonel Trebicka
Journal:  Lancet Reg Health Eur       Date:  2021-11-04

Review 8.  Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.

Authors:  Catherine T Frenette; Cynthia Levy; Sammy Saab
Journal:  Dig Dis Sci       Date:  2021-06-24       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.